New therapies for nontuberculous mycobacterial lung infection

Sarah J. Chalmers, Timothy R. Aksamit

Research output: Contribution to journalReview articlepeer-review


Purpose of reviewAlthough nontuberculous mycobacterial pulmonary disease is increasing in incidence, outcomes remain less than optimal highlighting the unmet need for developing novel therapies.Recent findingsSeveral new antibiotic formulations, novel antibiotics, and novel nonantibiotic treatments have recently demonstrated positive results in treating nontuberculous mycobacterial pulmonary disease.SummaryPromising novel therapies are currently under investigation fueling much needed interest and enthusiasm in the nontuberculous mycobacterial pulmonary disease space and will hopefully lead to improved understanding and outcomes in this complex disease.

Original languageEnglish (US)
Pages (from-to)176-184
Number of pages9
JournalCurrent Opinion in Infectious Diseases
Issue number2
StatePublished - Apr 1 2022


  • antibacterial agents
  • bacteriophages
  • lung disease
  • nontuberculous mycobacteria
  • therapy

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'New therapies for nontuberculous mycobacterial lung infection'. Together they form a unique fingerprint.

Cite this